Expertise in
20
conditions

Dr. Tawnya L. Bowles

Oncology
5121 S Cottonwood St, 
Murray, UT 
Accepting New Patients
Offers Telehealth
Expertise in
20
conditions
5121 S Cottonwood St, 
Murray, UT 

Overview

Tawnya Bowles is an Oncologist practicing medicine in Murray, Utah.

Dr. Bowles is highly rated in 20 conditions, according to our data. Her clinical expertise encompasses Melanoma, Liposarcoma, Merkel Cell Carcinoma, Mesenchymoma, and Reconstructive Urology Surgery.

Dr. Bowles is board certified in American Board Of Internal Medicine. She is actively involved in clinical research, co-authoring 37 peer reviewed articles and participating in 5 clinical trials. Dr. Bowles is currently accepting new patients.

Specialties

Oncology

Licenses

Surgery in UT

Board Certifications

American Board Of Internal Medicine

Hospital Affiliations

Intermountain Medical Center
Lds Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

BridgeSpan
  • EPO
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Regence
  • EPO
  • PPO
SelectHealth
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 2 Less Insurance Carriers -

Locations

Imed Physicians
5121 S Cottonwood St, Murray, UT 84107

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
A Phase II and Pilot Trial of PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM)
A Phase II and Pilot Trial of PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM)
Enrollment Status: Active_not_recruiting
Publish Date: July 07, 2026
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors [IGNYTE]
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors [IGNYTE]
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2026
Intervention Type: Biological
Study Drugs: RP1, Nivolumab
Study Phase: Phase 2
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drugs: Ipilimumab, IMO-2125
Study Phase: Phase 3
View 4 Less Clinical Trials

37 Total Publications

Corrigendum to "The benefit of sentinel lymph node biopsy in elderly patients with melanoma: A retrospective analysis of SEER-Medicare data (2010-2018)" [Am J Surg 237 (2024) 115896].
Corrigendum to "The benefit of sentinel lymph node biopsy in elderly patients with melanoma: A retrospective analysis of SEER-Medicare data (2010-2018)" [Am J Surg 237 (2024) 115896].
Journal: American journal of surgery
Published: May 21, 2026
Similar Doctors
Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required

Hematology-Oncology - Nielsen Rehabilitation Hospital

85 N Medical Dr, 
Salt Lake City, UT 
 (8.3 miles away)
801-585-0100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Neeraj Agarwal is an Oncologist practicing medicine in Salt Lake City, Utah. Dr. Agarwal is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Orchiectomy, and Tissue Biopsy. Dr. Agarwal is board certified in American Board Of Internal Medicine. Dr. Agarwal is currently accepting new patients.

Expertise in
19
conditions
Expertise in
19
conditions
Referral may be required

Hematology-Oncology - Nielsen Rehabilitation Hospital

85 N Medical Dr, 
Salt Lake City, UT 
 (8.3 miles away)
801-585-0100
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Ignacio Garrido-Laguna is an Oncologist practicing medicine in Salt Lake City, Utah. Dr. Garrido-Laguna is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatoblastoma, and Pancreatectomy. Dr. Garrido-Laguna is board certified in American Board Of Internal Medicine. Dr. Garrido-Laguna is currently accepting new patients.

Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required

Utah Cancer Specialists

3838 S 700 E Ste 100, 
Salt Lake City, UT 
 (3.8 miles away)
801-281-6860
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jose Pacheco is an Oncologist practicing medicine in Salt Lake City, Utah. Dr. Pacheco is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer. Dr. Pacheco is board certified in American Board Of Internal Medicine. Dr. Pacheco is currently accepting new patients.

Frequently Asked Questions about Dr. Tawnya L. Bowles

How do I make an appointment with Dr. Tawnya L. Bowles?

You can book an appointment with Dr. Tawnya L. Bowles by calling their office at 801-507-3380. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Tawnya L. Bowles a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Tawnya L. Bowles is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Tawnya L. Bowles specialize in?

While Dr. Tawnya L. Bowles is a Oncology, they have specific expertise in Melanoma, Liposarcoma, and Merkel Cell Carcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Tawnya L. Bowles participate in research or clinical trials?

Yes. Dr. Tawnya L. Bowles has published 37 articles and abstracts on conditions like Melanoma. You can view a list of Dr. Tawnya L. Bowles's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Tawnya L. Bowles accept my insurance?

Dr. Tawnya L. Bowles accepts most major insurance plans, including BridgeSpan and Cigna. We recommend calling the office directly at 801-507-3380 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bowles's expertise for a condition
ConditionClose
    View All 19 Advanced Conditions
    View All 15 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile